Article Versions Notes

Čermáková L, Hofman J, Laštovičková L, Havlíčková L, Špringrová I, Novotná E, Wsól V. Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. Pharmaceutics. 2022; 14(10):1994. https://doi.org/10.3390/pharmaceutics14101994

Čermáková, Lucie, Jakub Hofman, Lenka Laštovičková, Lucie Havlíčková, Ivona Špringrová, Eva Novotná, and Vladimír Wsól. 2022. "Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux" Pharmaceutics 14, no. 10: 1994. https://doi.org/10.3390/pharmaceutics14101994

Čermáková, L., Hofman, J., Laštovičková, L., Havlíčková, L., Špringrová, I., Novotná, E., & Wsól, V. (2022). Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib Effectively Modulates Cancer Resistance by Inhibiting Anthracycline Metabolism and Efflux. Pharmaceutics, 14(10), 1994. https://doi.org/10.3390/pharmaceutics14101994